In patients with advanced metastatic or incurable recurrent breast cancer with HER2-negative regardless of PD-L1 expression, we examined the effectiveness and safety of nivolumab, bevacizumab, and paclitaxel as the first-line triple treatment in NEWBEAT (WJOG9917B). Here, CD274 is linked to breast carcinoma.